This suggests that the FAK pathway is more activated in SCLC than in NSCLC and that FAK may be a good anti-cancer target in SCLC, alone or in combination with chemotherapy, immunotherapy, and/or radiotherapy. This evidence concerns the gene PTK2 and small cell lung carcinoma.